Nocturnal hypoxemia and prognosis in patients with acute symptomatic pulmonary embolism.

Data de publicació: Data Ahead of Print:

Autors de IIS La Fe

Autors aliens a IIS La Fe

  • Barbero, Esther
  • Manas, Eva
  • Retegui, Ana
  • Alberto-Garcia-Ortega
  • Garcia-Sanchez, Aldara
  • Cano-Pumarega, Irene
  • Jimenez, David

Grups d'Investigació

Abstract

BACKGROUND: Nocturnal hypoxemia has been associated with cardiovascular and non-cardiovascular morbidity and mortality. This study aimed to investigate the prognostic value of nocturnal hypoxemia among patients with hemodynamically stable acute symptomatic pulmonary embolism (PE). METHODS: We performed an ad hoc secondary analysis of clinical data from a prospective cohort study. Nocturnal hypoxemia was measured by the percent sleep registry with oxygen saturation <90% [TSat90]). Outcomes assessed over the 30-days after the diagnosis of PE included PE-related death, other cardiovascular deaths, clinical deterioration requiring an escalation of treatment, recurrent venous thromboembolism (VTE), acute myocardial infarction [AMI], or stroke. RESULTS: Of the 221 hemodynamically stable patients with acute PE from which the TSat90 could be calculated and did not receive supplemental oxygen, the primary outcome occurred in 11 (5.0%; 95% confidence interval [CI], 2.5% to 8.7%) within 30-days after the diagnosis of PE. When categorized by quartiles, TSat90 was not significantly associated with the occurrence of the primary outcome in unadjusted Cox regression analysis (hazard ratio, 0.96; 95% CI, 0.57 to 1.63; P?=?0.88), or after adjustment for body mass index (adjusted hazard ratio, 0.97; 95% CI, 0.57 to 1.65; P?=?0.92). When examined as a completely continuous variable (between 0 and 100), TSat90 was not associated with a significant increase in the adjusted hazard of 30-day primary outcome rates (hazard ratio, 0.97; 95% CI, 0.86 to 1.10; P?=?0.66). CONCLUSIONS: In this study, nocturnal hypoxemia did not identify stable patients with acute symptomatic PE at increased risk for adverse cardiovascular events.

Copyright © 2023. Published by Elsevier B.V.

Dades de la publicació

ISSN/ISSNe:
0167-5273, 1874-1754

INTERNATIONAL JOURNAL OF CARDIOLOGY  ELSEVIER IRELAND LTD

Tipus:
Article
Pàgines:
131148-131148
PubMed:
37423569
Factor d'Impacte:
1,195 SCImago
Quartil:
Q1 SCImago

Documents

  • No hi ha documents

Mètriques

Filiacions

Filiacions no disponibles

Keywords

  • Nocturnal hypoxemia; Prognosis; Pulmonary embolism

Campos d'Estudi

Projectes associats

INTENSIFICACION DR. MIGUEL MARTINEZ GARCIA

Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA

INT11/037 . 2012

ASOCIACION ENTRE TRASTORNOS RESPIRATORIOS DEL SUEÑO Y TASA DE CRECIMIENTO DEL MELANOMA CUTANEO

Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA

PI12/01363 . INSTITUTO DE SALUD CARLOS III . 2013

EFECTO DEL TRATAMIENTO CON CPAP SOBRE LAS CIFRAS TENSIONALES EN PACIENTES CON HIPERTENSION ARTERIAL REFRACTARIA. ESTUDIO MULTICENTRICO Y ALEATORIZADO. ESTUDIO HIPARCO

Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA

PI09/01647 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2010

INTENSIFICACION DR. MIGUEL ANGEL MARTINEZ GARCIA

Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA

INT14/00003 . INSTITUTO DE SALUD CARLOS III . 2015

ASOCIACIÓN ENTRE LOS TRASTORNOS RESPIRATORIOS DEL SUEÑO Y EL PRONÓSTICO DEL MELANOMA. ESTUDIO LONGITUDINAL Y MULTICÉNTRICO EN 443 PACIENTES CON MELANOMA CUTÁNEO MALIGNO.

Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA

PI16/01772 . INSTITUTO DE SALUD CARLOS III . 2017

Estudio piloto para la obtención de ovocitos maduros mediante maduración in vitro en mujeres donantes de ovocitos

Investigador Principal: ERNESTO BOSCH APARICIO

FPU18/01647 . MINISTERIO DE CIENCIA E INNOVACION . 2019

P4COPD: Prediction, Prevention, Personalized and Precision management of COPD in young adults.

Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA

PMP21/00090 . INSTITUTO DE SALUD CARLOS III . 2022

Registro nacional de antibóticos inhalados en patología crónica de la vía área.

Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA

REPAIR . 2023

Compartir la publicació